A poor quarter for Roche leads to muted expectations
Launching a suite of Covid-19 diagnostics could not prevent Roche’s first-half profits sliding 5%.
Covid-19 takes a toll on medtech’s first quarter
Medtronic has had a poor quarter owing to the pandemic – but Zimmer’s has been even worse.
Big Pharma remains bullish in the face of Covid-19
So far so good, as much of pharma shrugs off the full-year impact of Covid-19.
Long term forecasts confirm Keytruda’s dominance
Keytruda sales could be more than double any other product in 2026, new estimates suggests, as Merck’s cancer drug surges into the record books.
